A variant on the kappa opioid receptor gene (OPRK1) is associated with stress response and related drug craving, limbic brain activation and cocaine relapse risk

Translational Psychiatry

Volumn 3, Issue , 2013, Pages

  Xu, K ^a   Seo, D ^a   Hodgkinson, C ^b   Hu, Y ^c   Goldman, D ^b   Sinha, R ^a,d,e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e YALE UNIVERSITY   (United States)

Author keywords

Cocaine craving; Limbic midbrain hyperactivation; OPRK1; Relapse; Stress

Indexed keywords

COCAINE; HYDROCORTISONE; KAPPA OPIATE RECEPTOR; DOPAMINE UPTAKE INHIBITOR; OPRK1 PROTEIN, HUMAN;

ADULT; AFRICAN AMERICAN; ARTICLE; COCAINE DEPENDENCE; FEMALE; FOLLOW UP; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HUMAN; HYDROCORTISONE BLOOD LEVEL; LABORATORY DIAGNOSIS; LIMBIC SYSTEM; MAJOR CLINICAL STUDY; MALE; NERVE POTENTIAL; OPIATE ADDICTION; RECURRENCE RISK; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STRESS; AMYGDALOID NUCLEUS; BRAIN; CEREBELLUM; FUNCTIONAL NEUROIMAGING; GENETICS; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MENTAL STRESS; MESENCEPHALON; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; RECURRENT DISEASE; SECRETION (PROCESS); THALAMUS; WITHDRAWAL SYNDROME;

ADULT; AFRICAN AMERICANS; AMYGDALA; BRAIN; CEREBELLUM; COCAINE; COCAINE-RELATED DISORDERS; DOPAMINE UPTAKE INHIBITORS; FEMALE; FUNCTIONAL NEUROIMAGING; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; HYPOTHALAMUS; LIMBIC SYSTEM; MAGNETIC RESONANCE IMAGING; MALE; MESENCEPHALON; MIDDLE AGED; PITUITARY-ADRENAL SYSTEM; RECEPTORS, OPIOID, KAPPA; RECURRENCE; STRESS, PSYCHOLOGICAL; SUBSTANCE WITHDRAWAL SYNDROME; THALAMUS;

EID: 84883068088     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2013.62     Document Type: Article

References (62)

1. Sinha R. New findings on biological factors predicting addiction relapse vulnerability. Curr Psychiatry Rep 2011; 13: 398-405.
2. Sinha R, Fox HC, Hong KA, Bergquist K, Bhagwagar Z, Siedlarz KM. Enhanced negative emotion and alcohol craving, and altered physiological responses following stress and cue exposure in alcohol dependent individuals. Neuropsychopharmacology 2009; 34: 1198-1208.
3. Sinha R, Garcia M, Paliwal P, Kreek MJ, Rounsaville BJ. Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes. Arch Gen Psychiatry 2006; 63: 324-331. (Pubitemid 43345357)
4. Bruchas MR, Land BB, Chavkin C. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res 1314: 44-55.
5. Wadenberg ML. A review of the properties of spiradoline: a potent and selective kappaopioid receptor agonist. CNS Drug Rev 2003; 9: 187-198.
6. Pfeiffer A, Brantl V, Herz A, Emrich HM. Psychotomimesis mediated by kappa opiate receptors. Science 1986; 233: 774-776. (Pubitemid 16016229)
7. Bals-Kubik R, Ableitner A, Herz A, Shippenberg TS. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. The J Pharmacol Exp Ther 1993; 264: 489-495. (Pubitemid 23309241)
8. Butelman ER, Yuferov V, Kreek MJ. kappa-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci 2012; 35: 587-596.
9. Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WC Jr. et al. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 2003; 305: 323-330. (Pubitemid 36373867)
10. Carlezon WA Jr., Beguin C, DiNieri JA, Baumann MH, Richards MR, Todtenkopf MS et al. Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 2006; 316: 440-447. (Pubitemid 41832624)
11. Przewlocki R, Lason W, Hollt V, Silberring J, Herz A. The influence of chronic stress on multiple opioid peptide systems in the rat: pronounced effects upon dynorphin in spinal cord. Brain Res 1987; 413: 213-219. (Pubitemid 17112969)
12. Land BB, Bruchas MR, Lemos JC, Xu M, Melief EJ, Chavkin C. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J Neurosci 2008; 28: 407-414.
13. Bilkei-Gorzo A, Racz I, Michel K, Mauer D, Zimmer A, Klingmuller D et al. Control of hormonal stress reactivity by the endogenous opioid system. Psychoneuroendocrinology 2008; 33: 425-436.
14. McLaughlin JP, Li S, Valdez J, Chavkin TA, Chavkin C. Social defeat stress-induced behavioral responses are mediated by the endogenous kappa opioid system. Neuropsychopharmacology 2006; 31: 1241-1248. (Pubitemid 43971840)
15. Koob GF. A role for brain stress systems in addiction. Neuron 2008; 59: 11-34. (Pubitemid 351905857)
16. McLaughlin JP, Land BB, Li S, Pintar JE, Chavkin C. Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning. Neuropsychopharmacology 2006; 31: 787-794.
17. Fox HC, Talih M, Malison R, Anderson GM, Kreek MJ, Sinha R. Frequency of recent cocaine and alcohol use affects drug craving and associated responses to stress and drug-related cues. Psychoneuroendocrinology 2005; 30: 880-891. (Pubitemid 40977910)
18. Hyman SM, Fox H, Hong KI, Doebrick C, Sinha R. Stress and drug-cue-induced craving in opioid-dependent individuals in naltrexone treatment. Exp Clin Psychopharmacol 2007; 15: 134-143. (Pubitemid 47445242)
19. Breese GR, Chu K, Dayas CV, Funk D, Knapp DJ, Koob GF et al. Stress enhancement of craving during sobriety: a risk for relapse. Alcoholism Clin Exp Res 2005; 29: 185-195. (Pubitemid 40250507)
20. Sinha R, Fuse T, Aubin LR, O'Malley SS. Psychological stress, drug-related cues and cocaine craving. Psychopharmacology 2000; 152: 140-148.
21. Karpyak VM, Winham SJ, Preuss UW, Zill P, Cunningham JM,Walker DL et al. Association of the PDYN gene with alcohol dependence and the propensity to drink in negative emotional states. Int J Neuropsychopharmacol 2013; 16: 975-985.
22. Wee S, Koob GF. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology 2010; 210: 121-135.
23. Ungless MA, Argilli E, Bonci A. Effects of stress and aversion on dopamine neurons: implications for addiction. Neurosci Biobehav Rev 2010; 35: 151-156.
24. Hurd YL, Herkenham M. Molecular alterations in the neostriatum of human cocaine addicts. Synapse 1993; 13: 357-369. (Pubitemid 23104541)
25. Xuei X, Dick D, Flury-Wetherill L, Tian HJ, Agrawal A, Bierut L et al. Association of the kappa-opioid system with alcohol dependence. Mol Psychiatry 2006; 11: 1016-1024. (Pubitemid 44631644)
26. Zhang H, Kranzler HR, Yang BZ, Luo X, Gelernter J. The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk. Mol Psychiatry 2008; 13: 531-543. (Pubitemid 351556028)
27. Gerra G, Leonardi C, Cortese E, D'Amore A, Lucchini A, Strepparola G et al. Human kappa opioid receptor gene (OPRK1) polymorphism is associated with opiate addiction. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 771-775. (Pubitemid 47417206)
28. Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R et al. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcoholism Clin Exp Res 2007; 31: 555-563. (Pubitemid 46434892)
29. Loh el W, Fann CS, Chang YT, Chang CJ, Cheng AT. Endogenous opioid receptor genes and alcohol dependence among Taiwanese Han. Alcoholism Clin Exp Res 2004; 28: 15-19. (Pubitemid 38114019)
30. Ashenhurst JR, Bujarski S, Ray LA. Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol. Pharmacol Biochem Behav 2012; 103: 253-259.
31. Saito M, Ehringer MA, Toth R, Oros M, Szakall I, Sikela JM et al. Variants of kappa-opioid receptor gene and mRNA in alcohol-preferring and alcohol-avoiding mice. Alcohol 2003; 29: 39-49. (Pubitemid 36349121)
32. Edenberg HJ, Wang J, Tian H, Pochareddy S, Xuei X, Wetherill L et al. A regulatory variation in OPRK1, the gene encoding the kappa-opioid receptor, is associated with alcohol dependence. Hum Mol Genet 2008; 17: 1783-1789. (Pubitemid 351791504)
33. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV (Patient Edition). American Psychiatric Press Inc: Washington DC, 1995; 1995.
34. Sinha R. Modeling stress and drug craving in the laboratory: implications for addiction treatment development. Addict Biol 2009; 14: 84-98.
35. Sinha R, Talih M, Malison R, Cooney N, Anderson GM, Kreek MJ. Hypothalamic-pituitaryadrenal axis and sympatho-adreno-medullary responses during stress-induced and drug cue-induced cocaine craving states. Psychopharmacology 2003; 170: 62-72. (Pubitemid 37372479)
36. Sinha R, Lacadie C, Skudlarski P, Fulbright RK, Rounsaville BJ, Kosten TR et al. Neural activity associated with stress-induced cocaine craving: a functional magnetic resonance imaging study. Psychopharmacology 2005; 183: 171-180. (Pubitemid 41609269)
37. Sinha R. Modeling relapse situations in the human laboratory. Curr Top Behav Neurosci 2011.
38. Hodgkinson CA, Yuan Q, Xu K, Shen PH, Heinz E, Lobos EA et al. Addictions biology: haplotype-based analysis for 130 candidate genes on a single array. Alcohol Alcohol 2008; 43: 505-515.
39. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000; 155: 945-959. (Pubitemid 30397141)
40. Hommer RE, Seo D, Lacadie CM, Chaplin TM, Mayes LC, Sinha R et al. Neural correlates of stress and favorite-food cue exposure in adolescents: a functional magnetic resonance imaging study. Hum Brain Mapp advance online publication, 16 April 2012; doi: 10.1002/hbm.22089 (e-pub ahead of print).
41. Nolfe E. XMedCon-An open-source medical image conversion toolkit. Eur J Nucl Med 2003; 30(Suppl 2): S246.
42. Friston KJ, Holmes A, Poline JB, Price CJ, Frith CD. Detecting activations in PET and fMRI: levels of inference and power. Neuroimage 1996; 4(3 Pt 1): 223-235.
43. Duncan JS, Papademetris X, Yang J, Jackowski M, Zeng X, Staib LH. Geometric strategies for neuroanatomic analysis from MRI. Neuroimage 2004; 23(Suppl 1): S34-S45. (Pubitemid 39421705)
44. Holmes CJ, Hoge R, Collins L, Woods R, Toga AW, Evans AC. Enhancement of MR images using registration for signal averaging. J Comput Assist Tomogr 1998; 22: 324-333. (Pubitemid 28155214)
45. Cox RW. AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res 1996; 29: 162-173. (Pubitemid 26266657)
46. Seo D, Jia Z, Lacadie CM, Tsou KA, Bergquist K, Sinha R. Sex differences in neural responses to stress and alcohol context cues. Human Brain Mapping 2011; 32: 1998-2013.
47. Sinha R, Fox HC, Hong KI, Hansen J, Tuit K, Kreek MJ. Effects of adrenal sensitivity, stress-and cue-induced craving, and anxiety on subsequent alcohol relapse and treatment outcomes. Arch Gen Psychiatry 2011; 68: 942-952.
48. Sinha R. How does stress increase risk of drug abuse and relapse? Psychopharmacology 2001; 158: 343-359. (Pubitemid 33141310)
49. Sinha R. Chronic stress, drug use, and vulnerability to addiction. Ann NY Acad Sci 2008; 1141: 105-130.
50. Buckingham JC, Cooper TA. Pharmacological characterization of opioid receptors influencing the secretion of corticotrophin releasing factor in the rat. Neuroendocrinology 1986; 44: 36-40. (Pubitemid 16003083)
51. Nikolarakis K, Pfeiffer A, Stalla GK, Herz A. The role of CRF in the release of ACTH by opiate agonists and antagonists in rats. Brain Res 1987; 421: 373-376. (Pubitemid 18021649)
52. Laorden ML, Milanes MV. Effects of U-50 488H and U-50 488H withdrawal on catecholaminergic neurons of the rat hypothalamus. Life Sci 2000; 66: 803-815. (Pubitemid 30077852)
53. Ur E, Wright DM, Bouloux PM, Grossman A. The effects of spiradoline (U-62066E), a kappa-opioid receptor agonist, on neuroendocrine function in man. Br J Pharmacol 1997; 120: 781-784. (Pubitemid 27122716)
54. Pascoe JE, Williams KL, Mukhopadhyay P, Rice KC, Woods JH, Ko MC. Effects of mu, kappa, and delta opioid receptor agonists on the function of hypothalamic-pituitary-adrenal axis in monkeys. Psychoneuroendocrinology 2008; 33: 478-486.
55. Szeto HH. Dynorphin and the hypothalamo-pituitary-adrenal axis during fetal development. Life Sci 2003; 73: 749-758. (Pubitemid 36703269)
56. Mansour A, Fox CA, Akil H, Watson SJ. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci 1995; 18: 22-29.
57. Margolis EB, Lock H, Chefer VI, Shippenberg TS, Hjelmstad GO, Fields HL. Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. Proc Natl Acad Sci USA 2006; 103: 2938-2942.
58. Ganzel B, Casey BJ, Glover G, Voss HU, Temple E. The aftermath of 9/11: effect of intensity and recency of trauma on outcome. Emotion 2007; 7: 227-238. (Pubitemid 46800365)
59. Morris JS, Ohman A, Dolan RJ. A subcortical pathway to the right amygdala mediating 'unseen' fear. Proc Natl Acad Sci USA 1999; 96: 1680-1685. (Pubitemid 29098511)
60. Lanteaume L, Khalfa S, Regis J, Marquis P, Chauvel P, Bartolomei F. Emotion induction after direct intracerebral stimulations of human amygdala. Cereb Cortex 2007; 17: 1307-1313. (Pubitemid 47343616)
61. Behbehani MM. Functional characteristics of the midbrain periaqueductal gray. Prog Neurobiol 1995; 46: 575-605.
62. McNally GP, Pigg M, Weidemann G. Opioid receptors in the midbrain periaqueductal gray regulate extinction of pavlovian fear conditioning. J Neurosci 2004; 24: 6912-6919. (Pubitemid 39045448)